International Clinical Trial: A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07128121) titled 'A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older' on Aug. 11.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd

Condition: Respiratory Syncytial Virus (RSV) Infection

Intervention: Biological: Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006)

Recruitment Status: Recruiting

P...